Thursday, November 20, 2025
12:00 p.m. – 1:00 p.m. ET
Please note this TeleECHO program is 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.
PROGRAM CHAIR & PRESENTING FACULTY
 |
Claudine Isaacs, MD, FRCPC Professor of Medicine and Oncology Associate Director, Clinical Research Leader, Breast Cancer Program Co-Director, Fisher Center for Hereditary Cancer and Clinical Genomics Research Lombardi Comprehensive Cancer Center Georgetown University Washington, DC |
PROGRAM OVERVIEW
This virtually live interactive TeleECHO series is designed to advance your expertise in utilizing PI3K-pathway inhibitors for patients with hormone-receptor-positive, HER2-negative metastatic breast cancer. Combining didactic presentation with engaging case-based discussions alongside peers and expert faculty, the program explores personalized, multidisciplinary treatment strategies, effective adverse event management with an emphasis on blood sugar optimization, and key clinical challenges.
TARGET AUDIENCE
This innovative educational initiative is designed to meet the educational needs of community oncologists, oncology care team members (eg, pharmacists, advanced practice providers, nurses), and endocrinologists.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Select the most appropriate PI3K pathway inhibitor for patients with HR+/HER2- mBC based on the tumor mutational profile
- Summarize the mechanisms underlying hyperglycemia associated with PI3K pathway inhibitors, the characteristics of these AEs, and the impact on patients with HR+/HER2- metastatic breast cancer
- Develop strategies to monitor and manage hyperglycemia and other adverse events associated with PI3K pathway inhibitors effectively and promptly within an MDT
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, dietary, physical, etc). Please contact Med Learning Group prior to participating at [email protected]
